{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:11:27Z","timestamp":1782141087451,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004242","name":"Princess Nourah Bint Abdulrahman University","doi-asserted-by":"publisher","award":["PNURSP2025R917"],"award-info":[{"award-number":["PNURSP2025R917"]}],"id":[{"id":"10.13039\/501100004242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108494","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:40:09Z","timestamp":1745235609000},"page":"108494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights"],"prefix":"10.1016","volume":"160","author":[{"given":"Wagdy M.","family":"Eldehna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haytham O.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Nafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkulthom","family":"Al Kamaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar A.","family":"El-Hamaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"El Hassab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab M.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosra S.R.","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Balaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bioorg.2025.108494_bb0005","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1021\/acs.jmedchem.3c00640","article-title":"Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly(ADP-ribose) polymerase for BRCA wild-type breast Cancer therapy","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0425-1","article-title":"PARP inhibitors in the management of breast cancer: current data and future prospects","volume":"13","author":"Livraghi","year":"2015","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108494_bb0015","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.3390\/ijms24044044","article-title":"New approaches in early-stage NSCL management: potential use of PARP inhibitors and immunotherapy combination","volume":"24","author":"Fernandes","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108494_bb0020","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/acs.jmedchem.1c01714","article-title":"Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108494_bb0025","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/biomedicines9111512","article-title":"Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance","volume":"9","author":"Singh","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108494_bb0030","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jmb.2019.12.019","article-title":"Role of PARP-catalyzed ADP-ribosylation in the crosstalk between DNA strand breaks and epigenetic regulation","volume":"432","author":"Sutcu","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108494_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-319-14151-0_10","article-title":"Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents","author":"Murai","year":"2015","journal-title":"PARP Inhibitors Cancer Therapy"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108494_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300599","article-title":"Phthalimide-tethered isatins as novel poly (ADP-ribose) polymerase inhibitors: design, synthesis, biological evaluations, and molecular modeling investigations","volume":"357","author":"El Hassab","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.108494_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107829","article-title":"Design, synthesis, and in silico insights of novel N\u2019-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors","volume":"153","author":"Eldehna","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.07.044","article-title":"Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis","volume":"181","author":"Huang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104222","article-title":"Selective VEGFR-2 inhibitors: synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling","volume":"103","author":"AbdelHaleem","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13045-021-01196-x","article-title":"VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status","volume":"14","author":"Bizzaro","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12905-023-02879-y","article-title":"Efficacy and safety of VEGF\/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.bioorg.2025.108494_bb0070","series-title":"Targeting the DNA Damage Response for Cancer Therapy","first-page":"171","article-title":"Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents","author":"Lee","year":"2023"},{"issue":"492","key":"10.1016\/j.bioorg.2025.108494_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108494_bb0080","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2021.12.022","article-title":"Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy","volume":"12","author":"Pan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108494_bb0085","first-page":"2166","article-title":"Molecular docking and in vitro anticancer screening of synthesized arylthiazole linked 2H-indol-2-one derivatives as VEGFR-2 kinase inhibitors","volume":"22","author":"Shalmali","year":"2022","journal-title":"Anti-Cancer Agents Med. Chem. (Formerly Curr. Med. Chem.-Anti-Cancer Agents)"},{"key":"10.1016\/j.bioorg.2025.108494_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105622","article-title":"New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: design, synthesis, biological activities and in silico studies","volume":"120","author":"Abd El-wahab","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1039\/D4MD00621F","article-title":"Synthesis and anti-tumor activity of new benzofuran-based chalcone derivatives as potent VEGFR-2 inhibitors","volume":"16","author":"Zhang","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108494_bb0100","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/cells13191656","article-title":"Advances in cancer therapy: a comprehensive review of CDK and EGFR inhibitors","volume":"13","author":"Hawash","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108494_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106759","article-title":"Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors","volume":"139","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107278","article-title":"Recent development of VEGFR small molecule inhibitors as anticancer agents: a patent review (2021\u22122023)","volume":"146","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107556","article-title":"Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors","volume":"151","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108494_bb0120","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1021\/acs.jmedchem.9b00510","article-title":"Discovery and development of a series of Pyrazolo[3,4-d]pyridazinone compounds as the novel covalent fibroblast growth factor receptor inhibitors by the rational drug design","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0125","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14756366.2022.2062337","article-title":"Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights","volume":"37","author":"Eldehna","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107682","article-title":"Fragment-based design and synthesis of coumarin-based thiazoles as dual c-MET\/STAT-3 inhibitors for potential antitumor agents","volume":"151","author":"Naguib","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117158","article-title":"Design, synthesis, and evaluation of novel benzofuran and pyrazole-based derivatives as dual AChE\/BuChE inhibitors with antioxidant properties for Alzheimer\u2019s disease management","volume":"283","author":"Elkotamy","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108494_bb0140","doi-asserted-by":"crossref","first-page":"20438","DOI":"10.1021\/acs.jmedchem.4c01894","article-title":"4-(Pyrazolyl)benzenesulfonamide Ureas as carbonic anhydrases inhibitors and hypoxia-mediated chemo-sensitizing agents in colorectal Cancer cells","volume":"67","author":"Eldehna","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107626","article-title":"Unveiling the potential of isatin-grafted phenyl-1,2,3-triazole derivatives as dual VEGFR-2\/STAT-3 inhibitors: design, synthesis and biological assessments","volume":"151","author":"Elsebaie","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14756366.2023.2203389","article-title":"Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors","volume":"38","author":"Shaldam","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12906-020-02993-6","article-title":"Phytochemical profile and antiproliferative effect of Ficus crocata extracts on triple-negative breast cancer cells","volume":"20","author":"S\u00e1nchez-Valdeol\u00edvar","year":"2020","journal-title":"BMC Complement. Med. Therapies"},{"key":"10.1016\/j.bioorg.2025.108494_bb0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bioorg.2014.11.009","article-title":"Synthesis and in vitro evaluation of 3-(4-nitrophenyl) coumarin derivatives in tumor cell lines","volume":"58","author":"Musa","year":"2015","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115974","article-title":"Antimicrobial and cytotoxic effects of ammonium derivatives of diterpenoids steviol and isosteviol","volume":"32","author":"Voloshina","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/odi.15120","article-title":"Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines","volume":"31","author":"di Giacomo","year":"2025","journal-title":"Oral Dis"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108494_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202300848","article-title":"Analysis of Quinolinequinone analogs with promising cytotoxic activity against breast Cancer","volume":"20","author":"Yilmaz Goler","year":"2023","journal-title":"Chem. Biodivers."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108494_bb0180","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.3390\/ijms21228480","article-title":"Natural health products (NHP\u2019S) and natural compounds as therapeutic agents for the treatment of Cancer; mechanisms of anti-Cancer activity of natural compounds and overall trends","volume":"21","author":"Scaria","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bioorg.2025.108494_bb0185","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1002\/cam4.4052","article-title":"The promising role of antibody drug conjugate in cancer therapy: combining targeting ability with cytotoxicity effectively","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2025.108494_bb0190","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bioorg.2019.03.068","article-title":"Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold","volume":"87","author":"Elmasry","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108494_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27196203","article-title":"Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies","volume":"27","author":"Elkaeed","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108494_bb0200","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/ijms24031977","article-title":"Resveratrol derivative exhibits marked Antiproliferative actions, affecting Stemness in pancreatic Cancer cells","volume":"24","author":"Florio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108494_bb0205","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3390\/molecules29133186","article-title":"Identification of Benzothiazoles bearing 1,3,4-Thiadiazole as Antiproliferative hybrids targeting VEGFR-2 and BRAF kinase: design, synthesis, BIO evaluation and in silico study","volume":"29","author":"Ewes","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108494_bb0210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.phrs.2016.01.012","article-title":"Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1\/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells","volume":"105","author":"R.S, R","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0215","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1186\/s12885-015-2044-9","article-title":"Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ER\u03b1-negative breast tumorigenesis","volume":"15","author":"Romagnolo","year":"2015","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108494_bb0220","first-page":"1901","article-title":"PARP1-siRNA suppresses human prostate cancer cell growth and progression","volume":"39","author":"Lai","year":"2018","journal-title":"Oncol. Rep."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108494_bb0225","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4161\/15384101.2014.956507","article-title":"A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer","volume":"13","author":"Li","year":"2014","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108494_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12032-023-02279-0","article-title":"Combination of resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation","volume":"41","author":"Sinha","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2025.108494_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117485","article-title":"Design, synthesis and biological evaluation of dual inhibitors targeting AR\/AR-vs and PARP1 in castration resistant prostate cancer therapy","volume":"180","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"30","key":"10.1016\/j.bioorg.2025.108494_bb0245","doi-asserted-by":"crossref","first-page":"20443","DOI":"10.1039\/D3RA02579A","article-title":"Design, synthesis, and docking studies of novel pyrazole-based scaffolds and their evaluation as VEGFR2 inhibitors in the treatment of prostate cancer","volume":"13","author":"Soliman","year":"2023","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14756366.2021.2017911","article-title":"Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors","volume":"37","author":"Abdallah","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2024.107827","article-title":"Unveiling the anti-cancer potentiality of phthalimide-based analogues targeting tubulin polymerization in MCF-7 cancerous cells: rational design, chemical synthesis, and biological-coupled computational investigation","volume":"153","author":"Aljuhani","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13065-023-01014-0","article-title":"Design, synthesis, in vitro anticancer, molecular docking and SAR studies of new series of pyrrolo [2, 3-d] pyrimidine derivatives","volume":"17","author":"Sroor","year":"2023","journal-title":"BMC Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0265","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.msec.2017.03.085","article-title":"Heteroleptic silver(I) complexes with 2,2\u2032:6\u2032,2\u2033-terpyridines and naproxen: DNA interaction, EGFR\/VEGFR2 kinase, growth inhibition and cell cycle arrest studies","volume":"76","author":"Mahendiran","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.bioorg.2025.108494_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107455","article-title":"Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors","volume":"148","author":"Lin","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0275","article-title":"Anticancer effect of new cyclocoumarol derivatives","volume":"12","author":"Karaky","year":"2024","journal-title":"European J. Med. Chem. Rep."},{"key":"10.1016\/j.bioorg.2025.108494_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116527","article-title":"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments","volume":"274","author":"Hefny","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108494_bb0285","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.3390\/molecules25204606","article-title":"Significance of targeting VEGFR-2 and cyclin D1 in luminal-a breast Cancer","volume":"25","author":"Abdalla","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108494_bb0290","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1593\/neo.131604","article-title":"Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition","volume":"15","author":"Han","year":"2013","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108494_bb0295","first-page":"1220","article-title":"Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. International journal of radiation oncology* biology*","volume":"60","author":"Bischof","year":"2004","journal-title":"Physics"},{"key":"10.1016\/j.bioorg.2025.108494_bb0300","first-page":"1","article-title":"Anticancer and antiproliferative activities of Algerian Origanum majorana L.\u2019s essential oil on PC-3 and SKBR3 cells","author":"Nourehouda","year":"2024","journal-title":"J. Essent. Oil Bear. Plants"},{"key":"10.1016\/j.bioorg.2025.108494_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138641","article-title":"Integrated in silico and in vitro discovery of a new anticancer thiadiazole analog targeting VEGFR-2","volume":"1312","author":"Eissa","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108494_bb0310","first-page":"1554","article-title":"Downregulation of long non-coding RNA UCA1 enhances the radiosensitivity and inhibits migration via suppression of epithelial-mesenchymal transition in colorectal cancer cells","volume":"40","author":"Yang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2025.108494_bb0315","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejmech.2018.12.026","article-title":"Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis","volume":"163","author":"Aneja","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0320","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.5386","article-title":"Indole and 2,4-thiazolidinedione conjugates as potential anticancer modulators","volume":"6","author":"Corigliano","year":"2018","journal-title":"PeerJ"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108494_bb0325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jcb.21432","article-title":"Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects","volume":"103","author":"Rocha","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108494_bb0330","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3892\/or.2017.5501","article-title":"Stanniocalcin 1 promotes cell proliferation via cyclin E1\/cyclin-dependent kinase 2 in human prostate carcinoma","volume":"37","author":"Bai","year":"2017","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108494_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109170","article-title":"Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate Cancer cells via inhibition of Cdk2, CyclinA, and Skp2","volume":"9","author":"Kokontis","year":"2014","journal-title":"PLoS One"},{"issue":"60","key":"10.1016\/j.bioorg.2025.108494_bb0340","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.21973","article-title":"Inhibition of STAT3\/VEGF\/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108494_bb0345","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10059-010-0124-x","article-title":"Visfatin stimulates proliferation of MCF-7 human breast cancer cells","volume":"30","author":"Kim","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2025.108494_bb0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.108494_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117367","article-title":"Design, synthesis and biological evaluation of dual CDK9\/PARP inhibitors for the treatment of cancer","volume":"287","author":"Huang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116348","article-title":"Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy","volume":"270","author":"Qiu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0365","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mrrev.2017.09.004","article-title":"Poly-ADP ribosylation in DNA damage response and cancer therapy","volume":"780","author":"Hou","year":"2019","journal-title":"Mutation Res\/Rev. Mutation Res."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108494_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127109","article-title":"4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108494_bb0375","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/pharmaceutics12090838","article-title":"Biological evaluation of black chokeberry extract free and embedded in two mesoporous silica-type matrices","volume":"12","author":"Buda","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.108494_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137753","article-title":"Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors","volume":"1305","author":"Yousef","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0385","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/14756366.2022.2110869","article-title":"New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies","volume":"37","author":"Elkaeed","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108494_bb0390","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1021\/acs.jmedchem.3c00721","article-title":"1,5-Diaryl-1,2,4-triazole Ureas as new SLC-0111 analogues endowed with dual carbonic anhydrase and VEGFR-2 inhibitory activities","volume":"66","author":"Elsawi","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0395","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/acs.jmedchem.3c01708","article-title":"Lead optimization of BIBR1591 to improve its telomerase inhibitory activity: design and synthesis of novel four chemical series with in silico, in vitro, and in vivo preclinical assessments","volume":"67","author":"Al-Karmalawy","year":"2024","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108494_bb0400","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1021\/acs.jmedchem.4c00239","article-title":"Discovery and mechanistic studies of dual-target hits for carbonic anhydrase IX and VEGFR-2 as potential agents for solid tumors: X-ray, in vitro, in vivo, and in silico investigations of Coumarin-based Thiazoles","volume":"67","author":"Hefny","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108494_bb0405","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1021\/acs.jmedchem.3c02279","article-title":"Discovery of novel Pyridazine-tethered sulfonamides as carbonic anhydrase II inhibitors for the Management of Glaucoma","volume":"67","author":"Tawfik","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108494_bb0410","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108494_bb0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0420","doi-asserted-by":"crossref","first-page":"12821","DOI":"10.1038\/s41598-022-15050-8","article-title":"Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4,5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity","volume":"12","author":"Eldehna","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108494_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-5-367","article-title":"ACPYPE-antechamber python parser interface","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC. Res. Notes"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108494_bb0430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14756366.2021.2022659","article-title":"Multi-stage structure-based virtual screening approach towards identification of potential SARS-CoV-2 NSP13 helicase inhibitors","volume":"37","author":"El Hassab","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:59:12Z","timestamp":1777463952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825003748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":86,"alternative-id":["S0045206825003748"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108494","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108494"}}